Francine Foss, MD, reviews optimal management of a highly functional patient presenting with de novo tumor-stage mycosis fungoides.
Upon completion of this activity, participants should be able to:
Ibrutinib and the Management of Patients With del(17p) CLL
Acute Myeloid Leukemia: Will Understanding the Biology Lead to Better Outcomes?
FIRST Trial: Continuous Lenalidomide Plus Low-Dose Dexamethasone Improved PFS Over MPT in Elderly Patients With Newly Diagnosed Myeloma
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients With Myeloma
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.